Home › NDC Lookup › RxCUI directory › RxCUI 1665906

1 ML evolocumab 140 MG/ML Prefilled Syringe [Repatha] — RxCUI 1665906

Name: 1 ML evolocumab 140 MG/ML Prefilled Syringe [Repatha] (RxCUI 1665906)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1665906 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1665906

Official name1 ML evolocumab 140 MG/ML Prefilled Syringe [Repatha]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as1 ML Repatha 140 MG/ML Prefilled Syringe; Repatha 140 MG in 1 ML Prefilled Syringe

FDA products mapped4

Package NDCs mapped7

Reported Medicaid activity (SDUD)262,375 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Evolocumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Repatha is used for two main purposes. First, it lowers LDL ('bad') cholesterol — it's prescribed for adults with high cholesterol and for adults and kids aged 10 and older with an...
You inject Repatha under the skin — into your abdomen, thigh, or upper arm. The most important things to remember: let it warm up to room temperature for at least 30 minutes before...
How do I give myself this injection, and does it hurt?
The most common ones are pretty mild — cold symptoms, upper respiratory infections, flu, back pain, and occasional muscle aches. These usually aren't a reason to stop. What you do...

📖 Read our full Evolocumab Injection guide →

🕸️ Concept Web — How 1 ML evolocumab 140 MG/ML Prefilled Syringe [Rep... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 1 ML evolocumab 140 MG/ML Prefilled Syringe [Repatha] RxCUI 1665906 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Evolocumab 1665684 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Repatha 1665896 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Evolocumab Prefilled Syringe 1665903 SCDF
- Evolocumab Injectable Product 1665893 SCDG
- Evolocumab Prefilled Syringe [Repatha] 1665905 SBDF
- Repatha Injectable Product 1665899 SBDG
- Prefilled Syringe 721656 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 1 ML evolocumab 140 MG/ML Prefilled Syringe 1665904 SCD
- Evolocumab 140 MG/ML 1665892 SCDC
- Evolocumab 140 MG/ML [Repatha] 1665897 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

1 ML evolocumab 140 MG/ML Prefilled Syringe SCD · 1665904
Evolocumab 140 MG/ML SCDC · 1665892
Evolocumab Prefilled Syringe SCDF · 1665903
Evolocumab Injectable Product SCDG · 1665893

Brand-Name Concepts

Evolocumab 140 MG/ML [Repatha] SBDC · 1665897
Evolocumab Prefilled Syringe [Repatha] SBDF · 1665905
Repatha Injectable Product SBDG · 1665899
Repatha BN · 1665896

📦 FDA Products & Package NDCs

4 products · 7 package NDCs

7 package NDCs map to RxCUI 1665906 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
72511-0393-01	1 SYRINGE in 1 CARTON (72511-393-01) / 1 mL in 1 SYRINGE	REPATHA	Amgen USA Inc.	2024-11-24
72511-0393-02	2 SYRINGE in 1 CARTON (72511-393-02) / 1 mL in 1 SYRINGE	REPATHA	Amgen USA Inc.	2024-11-24
72511-0393-96	1 SYRINGE in 1 CARTON (72511-393-96) / 1 mL in 1 SYRINGE	REPATHA	Amgen USA Inc.	2024-11-24
72511-0501-01	1 SYRINGE in 1 CARTON (72511-501-01) / 1 mL in 1 SYRINGE	REPATHA	Amgen USA Inc.	2024-11-24
72511-0750-01	1 SYRINGE in 1 CARTON (72511-750-01) / 1 mL in 1 SYRINGE	REPATHA	Amgen USA Inc.	2018-10-09
72511-0760-02	2 SYRINGE in 1 CARTON (72511-760-02) / 1 mL in 1 SYRINGE (7...	REPATHA	Amgen USA Inc.	2018-10-09
72511-0760-91	1 SYRINGE in 1 CARTON (72511-760-91) / 1 mL in 1 SYRINGE	REPATHA	Amgen USA Inc.	2022-06-01

Observed labelers: Amgen USA Inc. (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$281.8590

Range $281.6970–$282.0210 · middle 50% $281.6970–$282.0210 · 4 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.